Overview of Aerus
The introductory definition of Aerus is anchored in its pharmaceutical identity, composition, and core purpose, providing clear, concise information for the patient.
| Property | Description |
|---|---|
| Active ingredient | Aprotinin (Polypeptide) |
| Form | Sterile Solution for Injection / Intravenous Infusion |
| Pharmacological class | Antifibrinolytic Agent, Serine Protease Inhibitor |
| Common use | Reducing blood loss during complex surgical procedures |
| Origin | Biological (Derived from Bovine Pulmonary Tissue) |
What Type of Medicine is Aerus (Aprotinin)?
Aerus is a specialized, prescription-only injectable medicine containing the active ingredient Aprotinin, primarily classified as an Antifibrinolytic Agent and a broad-spectrum Serine Protease Inhibitor. This classification means its role is focused on managing and controlling the body's natural systems for dissolving blood clots. As a hemostatic agent, Aerus is typically reserved for use in scenarios of high risk, such as complex cardiac or major orthopedic surgeries, where significant blood loss is anticipated and requires proactive management to reduce transfusion requirements.
Composition, Form, and Biological Origin
The active component, Aprotinin, is a high-molecular-weight polypeptide that gives the medicine its specific biological action. Uniquely, Aprotinin has a Biological Origin, historically derived from Bovine Pulmonary Tissue Extract, which distinguishes its complex protein structure from smaller, synthetically manufactured drugs. As a key differentiating factor, Aerus is consistently supplied as a Sterile Solution for Intravenous Infusion, meaning it is a liquid preparation administered directly into the bloodstream in a controlled clinical setting. This specific dosage form is necessary because the polypeptide structure requires direct systemic delivery to be effective, bypassing the digestive process.
What is the General Purpose of Aerus?
The general purpose of Aerus is to prevent or reduce excessive blood loss by stabilizing the body's clotting mechanisms. It achieves this by acting as a highly specific controller of the body's fibrinolysis process, which is the enzymatic breakdown of blood clots. By inhibiting key proteolytic enzymes responsible for dismantling the fibrin meshwork of a clot, Aprotinin ensures that clots formed during procedures remain intact and functional. This fundamental action is critical in clinical situations where the body’s clot control mechanisms are overactive, helping to maintain essential hemostasis and manage bleeding. This effect is designed to provide perioperative stability when the risk of excessive bleeding is substantial.
Regulatory References
